Ianalumab is a monoclonal antibody that is being investigated for autoimmune hepatitis, multiple sclerosis, pemphigus vulgaris, rheumatoid arthritis, Sjogren's disease, Immune thrombocytopenic purpura and systemic lupus erythematosus. From Wikipedia
The trial success paves the way for regulatory submissions, positioning the drug as the first targeted therapy to modify Sjögren’s disease course.
